BTIG Upgrades AVITA Medical to Buy, Announces $7 Price Target

Benzinga Newsdesk www.benzinga.com Positive 77.4%

Neg 0% Neu 0% Pos 77.4%

BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announces $7 price target.

Comments

No comments yet. Be the first!